Laura Shawver Sells 50,002 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 50,002 shares of the business’s stock in a transaction that occurred on Monday, April 7th. The shares were sold at an average price of $12.30, for a total value of $615,024.60. Following the completion of the sale, the director now owns 210,346 shares of the company’s stock, valued at $2,587,255.80. This trade represents a 19.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Laura Shawver also recently made the following trade(s):

• On Thursday, March 6th, Laura Shawver sold 49,600 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $11.21, for a total transaction of $556,016.00.
• On Monday, February 3rd, Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $12.31, for a total transaction of $615,500.00.

ARS Pharmaceuticals Price Performance

Shares of SPRY traded down $0.50 during trading hours on Tuesday, reaching $12.33. 1,485,520 shares of the company’s stock traded hands, compared to its average volume of 1,112,726. ARS Pharmaceuticals, Inc. has a twelve month low of $7.55 and a twelve month high of $18.51. The business’s fifty day simple moving average is $12.05 and its two-hundred day simple moving average is $13.07. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -24.18 and a beta of 0.86.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its quarterly earnings results on Thursday, March 20th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.56. The company had revenue of $86.58 million during the quarter, compared to analyst estimates of $15.46 million. On average, equities research analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SPRY. Oppenheimer began coverage on shares of ARS Pharmaceuticals in a report on Monday, February 10th. They issued an “outperform” rating and a $40.00 target price on the stock. Scotiabank assumed coverage on ARS Pharmaceuticals in a research report on Friday, March 7th. They set a “sector outperform” rating and a $30.00 price objective for the company. Leerink Partners raised their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. William Blair restated an “outperform” rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Finally, Raymond James lifted their price objective on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 14th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, ARS Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $31.00.

Hedge Funds Weigh In On ARS Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Bernard Wealth Management Corp. acquired a new position in ARS Pharmaceuticals during the fourth quarter worth about $27,000. GAMMA Investing LLC raised its holdings in shares of ARS Pharmaceuticals by 4,319.7% in the 1st quarter. GAMMA Investing LLC now owns 3,359 shares of the company’s stock worth $420,000 after purchasing an additional 3,283 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in ARS Pharmaceuticals during the fourth quarter valued at approximately $73,000. BNP Paribas Financial Markets acquired a new stake in ARS Pharmaceuticals during the fourth quarter valued at approximately $75,000. Finally, Compass Capital Corp MA ADV bought a new stake in ARS Pharmaceuticals during the fourth quarter worth approximately $106,000. 68.16% of the stock is currently owned by institutional investors and hedge funds.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.